All Title Author
Keywords Abstract


Absence of Hepatitis B Resistance Mutants before Introduction of Oral Antiviral Therapy

DOI: 10.1155/2013/130384

Full-Text   Cite this paper   Add to My Lib

Abstract:

Introduction. The aim of this study was to assess whether hepatitis B virus drug resistant mutations antedated the widespread use of nucleos(t)ide analogues in treatment na?ve patients. A number of reports have suggested that drug resistant mutants can be detected in apparently treatment na?ve patients. Study. Fifty deidentified serum samples collected from 1986 to 1992 from patients with replicative chronic HBV infection at the University of Miami were genotyped and tested for resistance mutations using a line probe assay InnoLiPA HBV DR v2/v3. Serum HBV DNA was measured. All patients had documented chronic HBV infection with a detectable viral load, HBeAg seropositivity, and absence of HIV infection. Results. Of the 50 individuals included, 86% were male, mean age was 40?±?12 years, and mostly genotype A. The mean HBV DNA was 126?pg/mL (range 6.4 to 557.0). No mutations were identified. Conclusions. The absence of drug induced mutations in these sera collected several years prior to the introduction of oral antiviral therapy suggests that these mutations do not occur in treatment na?ve populations. Detection of drug resistance in an apparently treatment na?ve subject suggests either unrecognized prior antiviral therapy or infection by an inoculum from a treatment experienced patient. 1. Introduction Infection with hepatitis B virus (HBV) remains a frequent etiology of cirrhosis and hepatocellular carcinoma with estimated 360 million individuals with chronic infection worldwide [1]. Although vaccination will ultimately reduce the disease burden due to HBV, antiviral therapy can favorably alter its natural history [2]. Goals of therapy include suppression of HBV replication to delay progression of liver disease reducing the risk of hepatic decompensation and hepatocellular carcinoma as well as infectivity to other individuals. Although standard interferon alpha was licensed for the treatment of chronic HBV infection over two decades ago more widespread therapy became feasible with the advent of well-tolerated oral antiviral nucleoside and nucleotide agents. However, shortly after the introduction of the first nucleoside analogue, lamivudine, treatment induced mutations in the viral genome were identified. These mutations resulted in reduced antiviral efficacy and diminished clinical benefit. Subsequently adefovir, a nucleotide analogue, efficacious in presence of lamivudine induced mutations was licensed, but its use was also associated with emergence of genomic antiviral resistance. Antiviral resistance has also been identified with more recently

References

[1]  S. T. Goldstein, F. Zhou, S. C. Hadler, B. P. Bell, E. E. Mast, and H. S. Margolis, “A mathematical model to estimate global hepatitis B disease burden and vaccination impact,” International Journal of Epidemiology, vol. 34, no. 6, pp. 1329–1339, 2005.
[2]  Y.-F. Liaw and C.-M. Chu, “Hepatitis B virus infection,” The Lancet, vol. 373, no. 9663, pp. 582–592, 2009.
[3]  E. B. Keeffe, D. T. Dieterich, S.-H. B. Han et al., “A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update,” Clinical Gastroenterology and Hepatology, vol. 6, no. 12, pp. 1315–1341, 2008.
[4]  A. S. F. Lok and B. J. McMahon, “AASLD practice guideline update chronic hepatitis B: update 2009,” Hepatology, vol. 50, no. 3, pp. 661–662, 2009.
[5]  A. S. Lok, F. Zoulim, S. Locarnini et al., “Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management,” Hepatology, vol. 46, no. 1, pp. 254–265, 2007.
[6]  Y.-F. Liaw, E. Gane, N. Leung et al., “2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B,” Gastroenterology, vol. 136, no. 2, pp. 486–495, 2009.
[7]  M. Matsuda, F. Suzuki, Y. Suzuki et al., “YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine,” Journal of Medical Virology, vol. 74, no. 2, pp. 361–366, 2004.
[8]  M. Matsuda, F. Suzuki, Y. Suzuki et al., “Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine,” Journal of Gastroenterology, vol. 39, no. 1, pp. 34–40, 2004.
[9]  S. Kobayashi, T. Ide, and M. Sata, “Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers,” Journal of Hepatology, vol. 34, no. 4, pp. 584–586, 2001.
[10]  S. Margeridon-Thermet, N. S. Shulman, A. Ahmed et al., “Ultra-deep pyrosequencing of hepatitis b virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients,” Journal of Infectious Diseases, vol. 199, no. 9, pp. 1275–1285, 2009.
[11]  S. Amini-Bavil-Olyaee, S. Y. Hosseini, F. Sabahi, and S.-M. Alavian, “Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine,” International Journal of Infectious Diseases, vol. 12, no. 1, pp. 83–87, 2008.
[12]  T. Pollicino, G. Isgrò, R. Di Stefano et al., “Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients,” Antiviral Therapy, vol. 14, no. 5, pp. 649–654, 2009.
[13]  Y. Han, L. H. Huang, C. M. Liu et al., “Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients,” Journal of Gastroenterology and Hepatology, vol. 24, no. 8, pp. 1417–1423, 2009.
[14]  M. H. Nguyen, R. T. Garcia, H. N. Trinh et al., “Prevalence of hepatitis B virus DNA polymerase mutations in treatment-na?ve patients with chronic hepatitis B,” Alimentary Pharmacology and Therapeutics, vol. 30, no. 11-12, pp. 1150–1158, 2009.
[15]  S. K. Fung, T. Mazzulli, M. El-Kashab, et al., “Lamivudine-resistant mutation among treatment-na?ve hepatitis B patients is common and may be associated with treatment failure,” Hepatology, vol. 48, supplement 1, p. 703A, 2008.
[16]  B.-M. Liu, T. Li, J. Xu et al., “Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-na?ve Chinese patients,” Antiviral Research, vol. 85, no. 3, pp. 512–519, 2010.
[17]  S. Mirandola, D. Campagnolo, G. Bortoletto, L. Franceschini, M. Marcolongo, and A. Alberti, “Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B,” Journal of Viral Hepatitis, vol. 18, no. 7, pp. e212–e216, 2011.
[18]  S. Fung, F. Wong, T. Mazzulli, et al., “Pre-existing antiviral-resistant mutation may be associated with primary non-response to lamivudine among treatment-na?ve chronic hepatitis B patients,” Hepatology, vol. 50, supplement 4, p. 523A, 2009.
[19]  R. Salpini, V. Svicher, V. Cento et al., “Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, na?ve to antiviral drugs,” Antiviral Research, vol. 92, no. 2, pp. 382–385, 2011.
[20]  M. Sayan, S. ?. Akhan, and M. Meric, “Naturally occurring amino-acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B,” Journal of Viral Hepatitis, vol. 17, no. 1, pp. 23–27, 2010.
[21]  C. Osiowy, K. A. Ng, J. Ho, et al., “Prevalence of nucleoside/nucleotide analogue resistance among treatment-na?ve endemically-exposed chronic hepatitis B individuals by ultra-deep pyrosequencing,” Hepatology, vol. 54, supplement 1, pp. 1067A–1068A, 2011.
[22]  K. A. Ng, C. Osiowy, D. K. Wong, et al., “Prevalence of lamivudine resistance mutations among treatment-naive endemically exposed chronic hepatitis B individuals is low and not linked to demographic predictors,” Hepatology, vol. 50, supplement 4, pp. 508A–509A, 2009.
[23]  M. H. Nguyen, H. N. Trinh, R. T. Garcia, et al., “No baseline mutations in the hepatitis B virus reverse transcriptase were detected in patients with treatment-naive chronic hepatitis B using INNO LIPA HBV DR 3: a prospective study,” Hepatology, vol. 50, supplement 4, p. 493A, 2009.
[24]  M. H. Nguyen, H. N. Trinh, R. T. Garcia, et al., “Hepatitis B virus (HBV) reverse transcriptase mutation is rare in treatment-naive patients with chronic hepatitis B, (CHB): a prospective multicenter study using INNO-LIPA HBV DR 3 assay,” Hepatology, vol. 54, supplement 1, p. 1080A, 2011.
[25]  M. A. Nowak, S. Bonhoeffer, A. M. Hill, R. Boehme, H. C. Thomas, and H. Mcdade, “Viral dynamics in hepatitis B virus infection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 9, pp. 4398–4402, 1996.
[26]  C. Osiowy, E. Giles, Y. Tanaka, M. Mizokami, and G. Y. Minuk, “Molecular evolution of hepatitis B virus over 25 years,” Journal of Virology, vol. 80, no. 21, pp. 10307–10314, 2006.
[27]  M. Solmone, D. Vincenti, M. C. F. Prosperi, A. Bruselles, G. Ippolito, and M. R. Capobianchi, “Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen,” Journal of Virology, vol. 83, no. 4, pp. 1718–1726, 2009.

Full-Text

comments powered by Disqus